A study in the British Journal of Cancer presents diagnostic whole-transcriptome sequencing applied to 1,233 formalin-fixed paraffin-embedded (FFPE) solid tumor samples, demonstrating feasibility and clinical-grade data yield across a large, heterogeneous cohort. The work, led by Ball, Beck, and Wlochowitz, validates transcriptome profiling on archival clinical material. Authors report that whole-transcriptome data can inform tumor classification, identify actionable expression signatures and support immune and pathway analyses from routine pathology specimens. The study advances integrative molecular diagnostics and suggests transcriptomic profiling could complement DNA-based assays in precision oncology workflows.